Clinical Trials Directory

Trials / Completed

CompletedNCT04394923

Relationship Between the Posterior Atrial Wall and the Esophagus: Esophageal Position and Temperature MEasurement During Atrial Fibrillation Ablation.

Impact of Pulmonary Vein Isolation (PVI) Line Modification Based on the Multidetector Computed Tomography (MDCT)-Derived Fingerprinted Esophageal Distance to the Posterior Wall of the Left Atrium, on the Esophageal Temperature Raise Measured With an Intraluminal Esophageal Temperature Monitoring Lead. A Randomized Controlled Study.

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
64 (actual)
Sponsor
Centro Medico Teknon · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

A multimodal strategy integrating esophageal visualization with the multidetector computed tomography (MDCT) and simultaneous temperature monitoring has never been put into practice. We have developed an isodistance map (esophageal print) to depict the atrio-esophageal relationship and to analyze the esophageal position peri procedurally. The present randomized study intends to analyze the usefulness of the esophageal print in predicting local thermal heating of the esophagus.

Detailed description

Primary objective: to validate the usefulness of the esophageal print in avoiding temperature rises caused by radiofrequency (RF) application at the left atrial (LA) posterior wall during atrial fibrillation ablation Secondary objectives: 1. to establish if there is a linear relationship between intraesophageal temperature rise and atrio-esophageal distance as calculated by the MDCT-derived esophageal print. 2. to analyze the need for ablation line modification. 3. to analyze the need for energy (power settings, ablation index, ablation time, etc.) modification. 4. to develop a new multimodal approach to esophageal monitoring during AF/AT ablation. Interventions 1. Pre-procedural scan and Esophageal Isodistance Print The methods for the acquisition of the cardiac MDCT and the image processing have been described in Part 1. During the segmentation process, the epicardial layer of the posterior atrial wall and the esophageal wall have been defined. The distance between these two structures is computed at each epicardial point, allowing to create an esophageal print on top of the epicardial layer. The isodistance color map uses a color scale to depict a range of distance; red being the closest (\< 1 mm) and purple being the most distant (\> 4 mm). Yellow, green and blue will be considered the intermediate values. 2. Luminal esophageal temperature (LET) monitoring A multi-thermocouple temperature probe (SensiTherm, St. Jude Medical, Inc., St. Paul, MN, USA) will be advanced via transnasal or transoral access into the esophagus once the patient is under general anesthesia. When the esophageal print is close to the ablation line, the temperature probe position will be adjusted under fluoroscopic guidance before application at each pair of pulmonary veins to ensure that it overlaps the ablation line. All esophageal temperature rises above 39 °C will be documented and RF application will be stopped. 3. Pulmonary vein ablation lines regarding Esophageal Isodistance Print Before randomization, an investigator blinded to the esophageal position will draw the PVI ablation line around both pairs of veins based on the type of AF (closer to the ostium for paroxysmal AF and wider for persistent AF).

Conditions

Interventions

TypeNameDescription
PROCEDUREModification of the pulmonary vein ablation lineThe ablation line previously drawn will be modified regarding the esophageal print position in order to avoid RF application within the red layer of the esophageal print.
PROCEDURERegular PVI ablationBlinded to the esophageal position based on the type of AF, closer to the ostium for paroxysmal AF and wider for persistent AF

Timeline

Start date
2020-06-22
Primary completion
2021-03-15
Completion
2022-01-15
First posted
2020-05-20
Last updated
2022-01-19

Locations

1 site across 1 country: Spain

Source: ClinicalTrials.gov record NCT04394923. Inclusion in this directory is not an endorsement.